A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Phase 3 Active not recruiting 752 enrolled Janssen Research & Development, LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Timeline

Start: 2025-04-15
Primary completion: 2025-11-17
Completion: 2027-08-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Icotrokinra	Peptide	—	Oral
Comparator	Ustekinumab	Monoclonal antibody	—	Subcutaneous

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Summary

Timeline

Drugs

Indications